Literature DB >> 12545300

[Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy].

L Faber1, H Seggewiss, D Welge, D Fassbender, P Ziemssen, H K Schmidt, U Gleichmann, D Horstkotte.   

Abstract

BACKGROUND AND
INTRODUCTION: Damage to the AV conduction system is a frequent complication of percutaneous septal ablation (PTSMA) that needs early and reliable identification of those patients (pts.) at risk for complete heart block (CHB) and subsequent pacemaker implantation. METHODS AND
RESULTS: In the first 39 pts. who underwent PTSMA in 1996, AV conduction recovery needed up to 11 days. One pt. suffered from unexpected CHB after 9 days. Seven pts. who needed a DDD pacemaker (DDD-PM) were compared to those without conduction disturbances. A score was established which identified all DDD-PM candidates retrospectively if they presented with >12 score points. In the following 137 consecutive pts. treated in 1997 and 1998, this score was applied prospectively, and again correctly identified all candidates for a DDD-PM. In addition, a low risk group was identified with <8 score points. From 1999 on, the score was applied in routine clinical decision-making in 120 consecutive pts. with respect to DDD-PM implantation. All low risk pts. (<8 points) remained free from bradycardias, while 2/54 pts. (4%) of the intermediate risk group, and 20/23 pts. (87%) of the high risk group had to undergo DDD-PM implantation. Pts. with a first-degree AV block or those with a right bundle branch block at baseline had no excess risk, while 50% of the pts. with a left bundle branch block (LBBB) needed a DDD-PM.
CONCLUSIONS: Based on pre-interventional data and careful monitoring of the first 48 hours after PTSMA, identification of pts. at risk for CHB and subsequent DDD-PM implantation seems to be possible. Pts. with a score <8 seem to be at low, those with >12 points at high risk. In the remaining cases watchful waiting with prolonged monitoring may allow AV conduction to recover, thus, reducing the number of unnecessary DDD-PM implantations. In cases with LBBB at baseline, however, implantation of a DDD-PM should be considered first-line therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12545300     DOI: 10.1007/s00392-003-0878-7

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  7 in total

1.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

2.  Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood.

Authors:  M Emmel; N Sreeram; J V deGiovanni; K Brockmeier
Journal:  Z Kardiol       Date:  2005-10

3.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

Review 4.  [Cardiomyopathies II. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy].

Authors:  H-P Schultheiss; M Noutsias; U Kühl; U Gross; D Lassner; W Poller; M Pauschinger
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

5.  Effect of transcoronary ablation of septal hypertrophy on clinical outcome in hypertrophic obstructive cardiomyopathy associated with atrial fibrillation.

Authors:  L Obergassel; T Lawrenz; F H Gietzen; F Lieder; C Leuner; H Kuhn; C Stellbrink
Journal:  Clin Res Cardiol       Date:  2006-03-21       Impact factor: 6.138

6.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Hicham El Masry; Jeffrey A Breall
Journal:  Curr Cardiol Rev       Date:  2008-08

7.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.

Authors:  I Sathyamurthy; Rajeshwari Nayak; Abraham Oomman; K Subramanyan; Mathew Samuel Kalarical; Robert Mao; P Ramachandran
Journal:  Indian Heart J       Date:  2013-12-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.